Published in J Natl Cancer Inst on December 30, 2015
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. Oncotarget (2017) 0.75
The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. BMC Cancer (2017) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res (2013) 6.17
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell (2011) 2.41
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res (2012) 2.14
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12
Inside and out: the activities of senescence in cancer. Nat Rev Cancer (2014) 1.96
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) (2009) 1.87
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res (2011) 1.64
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.63
BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res (2006) 1.54
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res (2013) 1.51
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51
Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal (2011) 1.41
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem (2011) 1.36
MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene (2000) 1.20
Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med (1995) 1.17
Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology (2013) 1.12
MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res (2010) 1.11
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol (2013) 1.09
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol (2013) 1.06
Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem (2012) 1.03
Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol (2013) 1.00
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res (2014) 0.90
Clinical deployment of antibodies for treatment of melanoma. Mol Immunol (2015) 0.82
Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. Oncoimmunology (2015) 0.77